To determine how pharmacokinetically advantageous acylation impacts on glucagon-like peptide-1 receptor (GLP-1R) signal bias, trafficking, anti-hyperglycaemic efficacy and appetite suppression.
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Introduction
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective agents for the treatment of type 2 diabetes (T2D) and obesity (1) . Their therapeutic effects derive mainly from potentiation of glucosestimulated insulin secretion and suppression of appetite leading to weight loss, respectively mediated by GLP-1Rs expressed in pancreatic beta cells and anorectic neurons. GLP-1RAs are known to improve renal (2) and cardiovascular outcomes (3) in T2D, and reduce mortality (4) .
The predominant intracellular signalling intermediate that couples GLP-1R activation to its downstream effects is cyclic adenosine monophosphate (cAMP) (5, 6) . However, an updated view of GLP-1R pharmacology highlights the roles of membrane trafficking (7, 8) and additional effector proteins such as the β-arrestins (9, 10) in the control of amplitude, duration and subcellular localisation of signalling events to regulate insulin secretion, particularly in the pharmacological setting. Although all clinically approved GLP-1RAs show broadly similar signalling and trafficking characteristics to the endogenous ligand, GLP-1(7-36)NH2, these can be dramatically altered via sequence modifications close to the ligand N-terminus, as demonstrated recently using analogues of the GLP-1 homologue peptide exendin-4 (11, 12) . Specifically, "biased" GLP-1RAs which retain full efficacy for cAMP production, but reduced β-arrestin recruitment and endocytic uptake, are able to avoid GLP-1R desensitisation and downregulation which ordinarily attenuate glucoregulatory responses in vivo.
Studies of orthosteric biased GLP-1R agonism have so far mainly used peptide ligands (11, 12) , sometimes featuring non-native amino acid substituents (13) (14) (15) . Whilst these ligands typically have been engineered for high proteolytic stability, rapid renal elimination (16) means that their half-lives are measured in hours, which is incompatible with a drive to reduce the frequency of injections for patient convenience, comfort and adherence. The leading GLP-1RAs in current clinical usage have been chemically optimised to allow once-weekly dosing in humans through avoidance of renal clearance (1), for example through conjugation of a fatty acid chain to the peptide which promotes reversible binding to albumin and other plasma proteins which are too large to undergo glomerular filtration. However, these approved compounds show broadly comparable signalling characteristics, and biased GLP-1R agonism has not yet been studied using pharmacokinetically optimised agents.
In this study, we investigate the impact of acylating two oppositely biased GLP-1R agonists, exendin-phe1 and exendin-asp3, both with identical amino acid sequences to exendin-4 except for at the first or third N-terminal amino acids, respectively (12) . We found that the introduction of a C-terminal fatty acid chain exaggerated the degree of bias at the expense of a reduced overall signalling potency for exendin-phe1-C16. However, when tested in vivo, despite up to ~1000-fold reduction in signalling potency, exendin-phe1-C16 outperformed exendin-asp3-C16 for control of blood glucose over 72 hours after a single dose, as well as providing greater glucose control and weight loss with repeated administration.
Materials and methods
Peptides
Peptides were obtained from Wuxi AppTec Co., Ltd., and were of >90% purity.
Cell culture
HEK293 cells stably expressing human SNAP-GLP-1R (17) hours at 4°C before measurement of binding by TR-FRET in a Flexstation 3 plate reader as previously described (17) . Binding was quantified as the ratio of fluorescent signal at 520 nm to that at 620 nm, after subtraction of the ratio obtained in the absence of FITC-ligands, and equilibrium binding constants (Kd) were calculated using Prism 8 (GraphPad Software).
Cyclic AMP responses
Cells were stimulated with agonist for the indicated time period in their respective growth mediums.
FBS was used when indicated. Assays were performed at 37°C without phosphodiesterase inhibitors except for with INS-1 832/3 and MIN6B1 cells, where 3-isobutyl-1-methylxanthine (IBMX) was added at 500 µM. At the end of the incubation period, cells were lysed, and cAMP was determined by homogenous time-resolved fluorescence (HTRF, cAMP Dynamic 2 kit, Cisbio).
β-arrestin recruitment
Cells were stimulated for 30 minutes in growth medium without FBS at 37°C. The assay was terminated by addition of PathHunter detection reagents and luminescent signal was read from each well.
NanoBiT assays
The plasmids for mini-Gs, -Gi and -Gq, each carrying an N-terminal LgBiT tag (19) , were a gift from and seeded in 96-well half area white plates. Baseline luminescence was measured over 5 minutes using a Flexstation 3 plate reader at 37°C before addition of ligand or vehicle. Responses were normalised to average baseline.
Confocal microscopy
HEK293-SNAP-GLP-1R cells seeded on coverslips were labelled with SNAP-Surface 549 prior to stimulation with indicated agonist (100 nM) for 30 minutes, after which cells were washed in PBS, fixed with 4% paraformaldehyde, mounted in Diamond Prolong mounting medium with DAPI, imaged with a Zeiss LSM780 inverted confocal microscope with a 63x/1.4 numerical aperture oil-immersion objective and analysed in Fiji.
Animal studies
All animal procedures were approved by the British Home for food intake assessments when they were individually caged with one week of acclimatisation prior to experiments.
Pharmacokinetic studies
Mice were injected intraperitoneally (IP) with 100 nmol/kg agonist and blood samples obtained by venesection into lithium heparin-coated capillary tubes. Plasma exendin concentrations were measured using a fluorescent enzyme immunoassay (Phoenix Pharmaceuticals) which recognises the C-terminus of exendin-4. A correction factor was applied to account for reduced recovery of acylated exendin-4 analogues, which was measured to be 50% of that of non-acylated exendin-4 when spiked into mouse plasma.
EScalate assay
The EScalate assay was performed as described previously (21) . Full methodological details are provided in Supplementary Methods.
Glucose tolerance testing
Mice were fasted for 4-5 hours before the test. Bodyweight-adjusted doses of glucose (2 g/kg) were injected IP, with or without agonist prepared within the same injector, as indicated. Blood samples were obtained immediately prior to injection and at 20-minute intervals thereafter, and glucose measured using a handheld glucose meter (GlucoRx).
Food intake
For sub-chronic studies, mice were fasted overnight and diet was returned to the cage immediately after IP injection of agonist, with cumulative intake determined by weighing. For the chronic study, mice were fasted for 4-5 hours during the light phase and diet was returned to the cage immediately after IP injection of agonist at the beginning of the dark phase.
Statistical analyses
Quantitative data were analysed using Prism 8.0 (GraphPad Software). In cell culture experiments, technical replicates were averaged so that each individual experiment was treated as one biological replicate. Dose responses were analysed using 4-parameter logistic fits, with constraints imposed as appropriate. Bias analyses were performed as previously described (12, 22) . 
Results
Impact of C-terminal acylation on in vitro pharmacology and trafficking of biased GLP-1RAs
The sequences of exendin-phe1, exendin-asp3, and their acylated equivalents exendin-phe1-C16
and exendin-asp3-C16, are given in Figure 1A . The C16 hexadecanedioic acid moiety was inserted at the peptide C-terminus after a lysine linker. This position was chosen to avoid the potential for the fatty acid to interfere with putative interactions made by the peptide N-terminus with the GLP-1R, which appear to be important for inducing signal bias. The equilibrium affinity of exendin-asp3-C16
was found to be similar to that of exendin-asp3 ( Figure 1B , log Kd -8.9 ± 0.1 versus -9.1 ± 0.1, respectively, p>0.05 by one-way randomised block ANOVA with Sidak's test), whereas exendin-phe1-C16 showed somewhat higher affinity for the receptor than its non-acylated counterpart (log Kd -8.3
± 0.0 versus -7.8 ± 0.0, respectively, p<0.05 by one-way randomised block ANOVA with Sidak's test).
Non-acylated exendin-phe1 is known to display markedly reduced recruitment of β-arrestin-1 and -2,
whereas non-acylated exendin-asp3 is a full agonist in these pathways, with both ligands being full agonists for cAMP (12) . To determine how acylation affects this established pattern of signal bias, we measured cAMP and β-arrestin-2 responses in PathHunter CHO-K1-βarr2-EA-GLP-1R cells. The expected signalling pattern was preserved ( Figure 1C , Table 1 ), although both C16 ligands showed reduced efficacy for β-arrestin-2 recruitment compared to their non-acylated equivalents. Despite increased binding affinity, cAMP potency for exendin-phe1-C16 was reduced compared to that of exendin-phe1. Due to the undetectable β-arrestin-2 response with exendin-phe1-C16, quantification of signal bias was not possible either using the most commonly used approach (23, 24) or using an alternative method (22) (Supplementary Figure 1A) .
Signalling potencies for cAMP at rat and mouse GLP-1Rs was also tested in INS-1 832/3 and MIN6B1 insulinoma cells, respectively (Supplementary Figure 1B , C, Table 1 ). In these cells, which express the GLP-1R endogenously, the potency shift with exendin-phe1-C16 was more pronounced (up to 1000-fold reduction in MIN6B1 compared to exendin-asp3-C16), accompanied by reduced efficacy in INS-1 832/3 cells. These differences are more marked than for cells with GLP-1R exogenously expressed at high levels, e.g. the experiments shown in Figure 1C .
We also used NanoBiT complementation to monitor dynamic interactions of both β-arrestin-2 (25) and the mini-Gs protein probe (19) with the GLP-1R after stimulation with a maximal concentration of each ligand ( Figure 1D ). Both phe1 ligands showed markedly reduced efficacy for Gs recruitment when compared to asp3 ligands, but as this was accompanied by almost undetectable β-arrestin-2 recruitment, the phe1 ligands appear to be genuinely biased in favour of G protein signalling. In a separate set of experiments we compared mini-Gs, -Gi and -Gq responses with each compound, confirming that Gs is the preferred G protein coupled to GLP-1R activation, but also revealing low magnitude Gq recruitment responses with both asp3 ligands (Supplementary Figure 1D ,E).
Next, the four ligands were compared in HEK293-SNAP-GLP-1R cells for their propensity to induce GLP-1R internalisation, as measured by diffusion-enhanced resonance energy transfer (DERET) assay (26) . Exendin-asp3 and exendin-asp3-C16 induced rapid internalisation, whereas none was detectable with either type of phe1 ligand ( Figure 1E , Supplementary Figure 1F , Table 1 ). These results were corroborated by confocal microscopy ( Figure 1F ).
This initial in vitro characterisation demonstrates that the C16 C-terminal conjugation is well tolerated by exendin-asp3. Some differences were however observed with the pharmacology of exendin-phe1, which showed increased binding affinity but decreased signalling efficacy, thereby magnifying signalling differences between the two oppositely biased ligands.
Acylated biased GLP-1RAs show prolonged pharmacokinetics
Acylation prolongs peptide pharmacokinetics by promoting reversible binding to plasma proteins that are too large to undergo glomerular filtration, such as albumin. To determine the extent of binding of exendin-phe1-C16, exendin-asp3-C16 and the similarly designed exendin-4-C16 ( Supplementary   Figure 2A ) to plasma proteins, we used the EScalate equilibrium shift assay (21) . Results indicated that each acylated ligand exhibited a high and similar degree of binding to mouse and human plasma proteins ( Table 2 ). In keeping with this, the presence of serum during the incubation did not differentially affect the signalling potency for each C16 ligand in GLP-1R cAMP assays compared to its non-acylated comparator (Supplementary Figure 2B) ; potency was in fact higher when serum was present for both acylated and non-acylated ligands, presumably due to reduced adsorption of peptide onto the microplate surface. In this system, an approximately 100-fold potency difference between exendin-phe1-C16 and exendin-asp3-C16 was observed, along with reduced efficacy for the former (Table 1 ).
In keeping with the anticipated pharmacokinetic effect resulting from binding to plasma proteins, after a single injection in mice, exendin-4-C16 remained detectable in the circulation for at least 72 hours, in contrast to non-acylated exendin-4 ( Figure 2A ). Similarly, exendin-phe1-C16 and exendin-asp3-C16 concentrations persisted for at least 72 hours ( Figure 2B ). We considered the possibility of whether GLP-1R-mediated clearance may play a role in pharmacokinetics once glomerular filtration is no longer a primary route of elimination, in a form of target-mediated drug disposal (TMDD) (27, 28) , but the absence of large differences in circulating concentrations of exendin-phe1-C16 and exendin-asp3-C16 at 24 and 72 hours post-dosing argues against this possibility.
Therefore, conjugation of a C16 diacid to the C-terminus of exendin-phe1 and exendin-asp3 results in a pair of pharmacokinetically advantageous and oppositely biased GLP-1RAs, allowing convenient assessment of the impact of signal bias and trafficking over multiple days.
Metabolic effects of biased GLP-1RAs are preserved after acylation
The primary therapeutic actions of GLP-1RAs are to improve glucose regulation and reduce appetite.
We trialled a series of doses of exendin-phe1-C16 and exendin-asp3-C16 in lean C57Bl/6 mice to assess their in vivo performance over 72 hours. Both ligands exhibited effective glucoregulatory properties acutely (Supplementary Figure 3A) , although exendin-phe1-C16 was less effective at 10 nmol/kg, which could reflect its reduced signalling potency. However, when reassessed at 72 hours, exendin-asp3-C16 no longer exhibited any detectable anti-hyperglycaemic efficacy, whereas both of the higher exendin-phe1-C16 doses remained effective. The acute anorectic effect of exendin-asp3-C16 was greater than that of exendin-phe1-C16, particularly at the 10 nmol/kg dose (Supplementary Figure 3B ), although, interestingly, by 72 hours, the net calorie intake deficit with exendin-phe1-C16 at the highest dose was greater than that of exendin-asp3-C16. Dose response analysis of these data is displayed in Supplementary Figure 3C .
We also tested both compounds at an intermediate dose in obese mice fed a high fat diet for 3 months.
Here, consistent patterns were observed, with equal glucose lowering seen 2 hours after dosing but a glycaemic advantage for exendin-phe1-C16 clearly demonstrated at 72 hours ( Figure 3A ). The anorectic differences were more subtle than in lean mice, with non-significant trends observed at 1 and 72 hours after dosing ( Figure 3B ). A non-significant trend was also seen for body weight loss, with exendin-phe1-C16-treated mice losing slightly more weight at 72 hours than those treated with exendin-asp3-C16 ( Figure 3C ).
The apparent greater efficacy with exendin-phe1-C16 at 72 hours suggest that the impact of its biased pharmacology is preserved in vivo, despite its considerably lower net signalling potency. As observed previously, these effects primarily concerned its glucoregulatory properties.
Sustained administration of acylated biased GLP-1RAs
We performed a repeated administration study in high fat diet-induced obese mice to compare the therapeutic effects of exendin-phe1-C16 and exendin-asp3-C16 in a chronic setting. Mice were injected every 72 hours over 15 days; the dose was doubled after the first 3 injections to counteract adaptive mechanisms typically seen in rodents treated with GLP-1RAs which limit weight loss (30) (31) (32) . Over the course of the study, the trends observed in the single dose administration studies became more apparent, with a progressively greater anorectic effect observed with exendin-phe1-C16, along with corresponding divergence in body weight (Figure 4A, B) . Glucose tolerance assessed 72 hours after the final dose confirmed the expected advantage of exendin-phe1-C16 over exendin-asp3-C16 ( Figure 4C ).
Thus, the metabolic benefits of the biased GLP-1RA exendin-phe1-C16 were preserved on repeated administration, and became progressively more apparent over time.
In the present study, we have developed and tested two oppositely biased GLP-1RAs bearing Cterminal C16 diacid chains, which confer extended pharmacokinetic profiles. The major observation from our data is that, despite at least large reduction in cAMP signalling potency (10-to 1000-fold, depending on cell system used), exendin-phe1-C16 is markedly more efficacious in vivo than oppositely biased exendin-asp3-C16. This finding builds on earlier reports highlighting the advantageous glucoregulatory properties of lower affinity biased GLP-1RAs which favour cAMP signalling over β-arrestin recruitment (11, 12) , but with a substantially greater disconnect between acute in vitro potency and anti-hyperglycaemic properties than for earlier compounds.
Some interesting in vitro observations arise from this work, particularly regarding comparisons of acylated versus non-acylated ligands. Firstly, we found that the binding affinity of exendin-phe1-C16 was approximately 3 times greater than that of non-acylated exendin-phe1, yet its cAMP signalling potency was between 5 and 20 times (for CHO-K1 and MIN6B1 cells, respectively) lower. One possible explanation for this would be that the acyl chain disrupts normal ligand-receptor interactions in a manner which permits ligand binding but orientates the ligand so that its N-terminus fails to engage optimally with the receptor core, leading to reduced levels of activation. Structural and computational studies will likely be required to reveal if is this is the case, and may be hampered by the lack of confidence about the position of the exendin-4 C-terminus when bound to GLP-1R (33) .
An alternative possibility, tentatively supported by recent reports that active GLP-1Rs segregate into cholesterol-rich nanodomains within the plasma membrane (17, 29) , is that the fatty acid preferentially directs the ligand to bind to subpopulations of GLP-1Rs residing in membrane regions with reduced enrichment of signalling effectors on the cytoplasmic side.
Addition of a C16 diacid moiety, as expected from other ligands tested as part of the preclinical development of C18 diacid-containing semaglutide (34, 35) , provided a high degree of binding to both mouse and human plasma proteins. The slightly lower affinity of the investigated compounds (2.08% -2.33% in human plasma) compared to Liraglutide, containing a C16 fatty acid moiety (0.51% in human plasma (21)), may be attributable to the shorter linker between the peptide and the albumin binding group. In combination with resistance of exendin peptides to degradation by a variety of enzymes including dipeptidyl dipeptidase-4 and neutral endopeptidases (36) , the two primary elimination routes for GLP-1 peptides are avoided, providing a basis for substantially extended pharmacokinetics in mice, with even longer protraction expected to be obtained in humans.
Our evaluation of the pharmacodynamic performance of biased GLP-1RAs found clear evidence of improved anti-hyperglycaemic efficacy for exendin-phe1-C16. This is in spite of substantially reduced acute signalling potency of this molecule, highlighting how standard in vitro approaches may fail to identify optimal agonist characteristics. Even though coupling to Gs recruitment was markedly reduced, it can be speculated that the virtual absence of β-arrestin recruitment, and of GLP-1R
internalisation, allow prolongation of signalling despite an initial deficit, as previously described (12) .
Interestingly, recent work has suggested that β-arrestins play a minimal role in controlling GLP-1R endocytosis (17) , and may not diminish acute insulin secretory responses from pancreatic beta cells (9, 37) . However, the latter observation needs to be evaluated under conditions of sustained exposure to pharmacokinetically optimised GLP-1RAs, in line with the appropriate timescales for glucoregulatory benefits of biased GLP-1RAs, which tend to emerge after a number of hours.
Interestingly, GLP-1R internalisation was reported to be Gq-dependent (38) , and with this in mind, it may be relevant that we detected Gq recruitment to the GLP-1R after treatment with fast-internalising -asp3 ligands.
It is notable that the differences in physiological response entrained by oppositely biased ligands concerned primarily their glucoregulatory effects, with smaller differences observed on feeding behaviour. A similar pattern has previously been noted with other biased GLP-1RAs (11, 12) , and this divergence has not yet been satisfactorily explained. Differential access to anorectic neurons within the central nervous system due to altered GLP-1R-mediated carriage across the blood brain barrier (39) , as well as differential actions of biased ligands on different cell types ["tissue bias" (40)]
remaining two realistic possibilities to be explored. Nevertheless, it should be highlighted that, in the present report, when administered chronically, exendin-phe1-C16 resulted in superior cumulative reductions in food intake and greater weight loss than exendin-asp3-C16. As exendin-phe-C16 tended to exert a milder appetite suppressive effect in the acute setting, enhanced tolerability might result whilst still achieving better weight loss and anti-hyperglycaemic efficacy.
In this study we did not compare these ligands against class-leading GLP-1RAs such as semaglutide and dulaglutide, and therefore their true therapeutic potential remains unclear. Nevertheless, our results clearly show that agonists displaying weak acute signalling efficacy and potency can be surprisingly effective for therapeutically important readouts. Understanding the molecular events which underpin their unusual pharmacology may also shed light on new ways to control GLP-1R behaviours in the future.
Table 1. Binding, signalling and internalisation parameter estimates for ligands in this study.
Signalling parameter measures were determined as follows: an initial 4-parameter fit was constructed for all full agonists, with globally constrained basal response, Emax and Hill slope, to establish the maximal response for the assay (note that for β-arrestin-2 measurement, Ex-asp3 was the only full agonist). Individual responses were normalised to the assay maximum and parameter estimates for each assay recalculated by 4-parameter fitting with globally constrained basal response and Hill slope, but no constraint to Emax. For internalisation, curve fitting was performed similarly but without prior normalisation to a maximal response. Note that for β-arrestin-2, meaningful estimates for Ex-phe1-C16 could not be calculated ("n.c."), as was also the case for both Ex-phe1 and Ex-phe1-C16 for internalisation. Average ± SEM values are reported. 
B C A
Exendin-phe1 F G E G T F T S D L S K Q M E E E A V R L F I E W L K N G G P S S G A P P P S NH2 Exendin-phe1-C16 F G E G T F T S D L S K Q M E E E A V R L F I E W L K N G G P S S G A P P P S G Lys
Exendin-4 F G E G T F T S D L S K Q M E E E A V R L F I E W L K N G G P S S G A P P P S NH2 Exendin-4-C16 F G E G T F T S D L S K Q M E E E A V R L F I E W L K N G G P S S G A P P P S G Lys
Supplementary data EScalate plasma protein binding assay
Plasma protein binding of Ex4-C16, Ex-asp3-C16 and Ex-phe1-C16 was determined using the 3BP EScalate Equilibrium Shift Assay. In short, the shift of the binding equilibrium of the compound to HSA-coated beads following addition of plasma at various dilutions was analysed. From this concentration-dependent shift, the apparent dissociation constants for binding to HSA on the beads and binding to plasma proteins can be calculated. From the apparent dissociation constant to plasma proteins, the fraction that is not bound to plasma proteins (fraction unbound, fu) can be calculated. 
Materials
Plasma dilutions
Following plasma dilutions were prepared for each assay. 
Sample generation
The Equilibrium Shift Assay samples were generated by addition of 30 µl of the prepared plasma dilutions (50%, 16.7%, 5.6%, 1.9% and 0.62%) and 5 µl of the 24 µM compound stock solution to each well. A binding protein concentration of 600 µM was assumed for all plasma samples. After 1 hour of incubation at room temperature under gentle shaking, the kit plate was centrifuged to separate the HSA immobilized on beads from the free plasma proteins. 50 µL of the supernatant were taken as sample from each vial. For calibration purposes, additional compound solutions in PBS were prepared by diluting the 24 µM stock solution as following: Calibration samples were prepared by spiking 120 µL of the lowest plasma / protein dilution with 5 µL of the compound spiking solution. The calibration samples were incubated together with the assay samples.
Sample preparation
Each sample was mixed with 2 µL of the 24 µM stock solution of the chosen internal standard and 250 µL of acidified acetonitrile (containing 1% trifluoroacetic acid) to precipitate the plasma proteins. The samples were centrifuged and 100 µL of the supernatants were diluted with 100 µL of 0.1% aqueous formic acid. 
Compound Chosen internal standard
Ex4-C16 Ex4-phe1-C16
Ex4-asp3-C16 Ex4-phe1-C16
Ex4-phe1-C16 Ex4-asp3-C16
LC-MS analysis
The samples were analyzed using an Agilent 1290 UHPLC system coupled to an Agilent 6470 triple quadrupole mass spectrometer.
Chromatographic parameters:
Column: Waters Acquity CSH C18, 50 x 2 mm, 1.7 µm where c0 is the total concentration of drug in the incubation, KD HSA is the dissociation constant of the compound from immobilized HSA on beads, KD Plasma is the dissociation constant of the compound from plasma proteins in solution, [HSA] bound is the concentration in solution of HSA bound to the beads, P is the concentration of the binding protein in plasma and α is the applied dilution factor. Then, the free fraction of the compound in plasma was calculated as follows (assuming a binding protein concentration of 600 µM for all plasma samples).
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To evaluate the assay a Total Quality Index (TQI) was calculated to evaluate the consistency with the applied binding model, uncertainty of the analysis method and differences in compound recovery at different plasma dilutions. The index can take values between zero and ten. A value of 8 or higher is indicating good assay performance.
Results
The results are given in Table 4 . The Total Quality Index (TQI) is an artificial value to describe the assay performance. It ranges from 1 to 10 and covers the consistency with the applied binding model, uncertainty of the analysis method and differences in compound recovery at different plasma dilutions. The index can take values between zero and ten. It is calculated as the mean of different quality indices which can also take values between zero and ten (see Table 5 ). A value of 8 or higher is indicating good assay performance. 
